Clearside Biomedical announces upcoming presentations on CLS-AX sub-group analyses from the ODYSSEY Wet AMD trial at various conferences. Clearside Biomedical, Inc. announced upcoming presentations ...

ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing ...